- RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - RecruitingPHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
This study, called iFIT, helps doctors find the best treatments for older myeloma patients. It checks how well standard NHS treatment works and looks at your fitness level. Then, it uses this information to decide the next steps, aiming to improve your care.
For: Multiple Myeloma (MM) · Plasma Cell Leukemia (PCL)United Kingdom - Active not recruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
For: Relapsed/Refractory Follicular Lymphoma · Marginal Zone LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
This study is looking at a new combination of four medicines (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) for people with newly diagnosed, high-risk multiple myeloma. It aims to see how safe and effective this treatment is.
For: Multiple MyelomaGermany - Active not recruitingPHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
This study looks at a new cell therapy called JNJ-68284528 for people with multiple myeloma. It aims to see how well it works in clearing up any remaining cancer cells after treatment.
For: Multiple MyelomaUnited States · Belgium · France - RecruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
For: Follicular LymphomaAustria · Belgium · France - Active not recruitingPHASE3
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
This study looks at a new drug combination, E-KRd, for people just diagnosed with multiple myeloma. It adds a drug called Elotuzumab to a standard treatment (KRd) to see if it works better at controlling the cancer and keeping it away for longer.
For: Newly Diagnosed Multiple MyelomaAustria · Germany - Active not recruitingPHASE1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, etentamig, along with existing cancer treatments for adults with multiple myeloma that has come back or isn't responding to treatment. We want to see how safe it is and if it helps reduce the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Germany - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
This study looks at a new combination of two drugs, tafasitamab and lenalidomide, for adults in the UK with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's for those whose cancer has returned or hasn't responded well to previous treatments and who can't have a stem cell transplant.
For: Large B-Cell Lymphoma · Diffuse Large B-Cell LymphomaBulgaria · Croatia · Czechia - Active not recruitingPHASE1
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
This study looks at a new drug, ABBV-453, for multiple myeloma that has come back or not responded to previous treatments. Researchers want to see if it's safe, what side effects it might cause, and if it helps to control the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Israel - RecruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
For: Multiple MyelomaGermany - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
This study compares two treatments for follicular lymphoma that has come back or not responded to previous treatments. It looks at a new drug, mosunetuzumab, combined with lenalidomide, versus a standard treatment, rituximab with lenalidomide, to see which works better and if they are safe.
For: Relapsed or Refractory Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE2
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This study looks at treating certain blood cancers with a drug called azacitidine. Researchers want to see if adding lenalidomide or vorinostat makes azacitidine work better. It’s for adults with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML).
For: Chronic Myelomonocytic Leukemia · Chronic Myelomonocytic Leukemia-1 · Chronic Myelomonocytic Leukemia-2United States · Canada - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
For: Diffuse Large B-cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
This study is testing a new combination of medicines for multiple myeloma, a type of blood cancer. It aims to find the safest and most effective dose of Belantamab mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone for people whose myeloma has returned or not responded to previous treatments.
For: Multiple MyelomaUnited States · Brazil · Canada - Active not recruitingPHASE1
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study looks at a new combination treatment for newly diagnosed multiple myeloma. It combines an existing drug, belantamab mafodotin, with standard treatments (VRd) to see if it's safe and effective, and to find the best dose.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
For: Multiple Myeloma · Newly Diagnosed Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
For: Non-Hodgkin LymphomaUnited States · China · Czechia - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
For: Multiple MyelomaUnited States · Australia · Austria - Not yet recruitingPHASE2
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
This study compares two treatments, Elranatamab with Lenalidomide, and Daratumumab with Lenalidomide, for people with newly diagnosed advanced blood cancer called multiple myeloma, after they've had a stem cell transplant. It aims to see which treatment works best to keep the cancer from coming back.
For: Multiple MyelomaFrance - Active not recruitingPHASE3
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
This study looks at different treatment plans for multiple myeloma after a stem cell transplant. It compares a drug called Lenalidomide with a combination of Lenalidomide and Daratumumab, to see which works best and for how long, based on how well the myeloma responds.
For: Multiple MyelomaUnited States · Canada - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is testing a new drug, linvoseltamab, for people with a type of blood cancer called multiple myeloma. It compares this new drug to standard treatments to see how safe and effective it is, for patients who cannot have a stem cell transplant.
For: Multiple MyelomaAustralia · Austria · Croatia - Active not recruitingPHASE3
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
This study is looking at a new treatment called isatuximab, combined with other treatments, for adults newly diagnosed with a type of blood cancer called multiple myeloma. It's for those who aren't able to have a stem cell transplant and aims to see if the new combination can help people live longer without their cancer getting worse.
For: Plasma Cell MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
This study looks at adding a new drug, Isatuximab, to standard treatment for newly diagnosed multiple myeloma. It aims to see if Isatuximab improves outcomes both during initial treatment and during ongoing maintenance therapy.
For: Multiple MyelomaGermany - Active not recruitingPHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This study looks at new treatments for younger adults with newly diagnosed multiple myeloma. It tests combinations of medications like teclistamab and talquetamab, depending on whether a small amount of cancer is still present after initial treatment. The goal is to find better ways to manage the disease.
For: Multiple MyelomaFrance - RecruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
For: Multiple MyelomaUnited States · Belgium · Brazil - Active not recruitingPHASE3
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
This study looks at whether adding two medicines, lenalidomide and dexamethasone, after radiotherapy for a type of bone cancer called solitary bone plasmacytoma, can stop it from turning into a more serious condition called multiple myeloma.
For: PlasmacytomaUnited Kingdom - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
For: Follicular Lymphoma (FL)United States · Argentina · Australia - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
For: Plasma Cell MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
This study looks at new drug combinations for follicular lymphoma. It checks how safe they are, how well they work, and how the body handles them. Researchers are comparing different ways to give one of the drugs.
For: Follicular LymphomaUnited States · China · France - Active not recruitingPHASE2
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
This study looks at new treatments for a type of blood cancer called Diffuse Large B-Cell Lymphoma in older patients who can't have standard chemotherapy. It tests a drug called epcoritamab, with or without another drug called lenalidomide, to see how well they work and if they are safe.
For: Diffuse Large B-Cell LymphomaUnited States · Austria · Belgium - Active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is looking at a new medicine called talquetamab, combined with other treatments, for people with multiple myeloma. The main goal is to find safe doses and understand how well these combinations work together.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments, Iberdomide and Lenalidomide, after a stem cell transplant for multiple myeloma. It aims to find out which one works better at keeping the cancer under control following initial treatment.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
For: Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)United States · Australia · Austria - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
For: Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
For: Follicular Lymphoma · Marginal Zone LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
This study looks at new treatments for multiple myeloma, a type of blood cancer. It compares a standard treatment plus a new cell therapy called cilta-cel, against the standard treatment alone, for people newly diagnosed who aren't having a stem cell transplant initially.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
This study compares a new cell therapy (ide-cel) plus standard maintenance medicine (lenalidomide) against lenalidomide alone for adults with newly diagnosed multiple myeloma. It's for those who haven't fully responded to their initial stem cell transplant.
For: Multiple MyelomaUnited States · Australia · Austria